An NCI-designated Comprehensive Cancer Center
Michelle Afkhami MD

Michelle Afkhami, M.D.

Clinical Expertise
  • Hematopathology
  • Molecular Genomic Pathology
Medical Director, Clinical Molecular Diagnostic Laboratory; Assistant Clinical Professor, Department of Pathology

Clinical Teams

  • Brain Tumors
  • Clinical Molecular Diagnostic Laboratory
  • Pathology
Michelle Afkhami, M.D., is an anatomic and clinical pathologist with subspecialties in Hematopathology and Molecular Genomic Pathology. She currently serves as a medical director of the Clinical Molecular Diagnostic Laboratory, chair of the multidisciplinary Genomic Tumor Board, and member of the Oversight Precision Medicine Committee at City of Hope. 
She received her medical degree in Iran and went on to complete two years of residency in general surgery at the University of Southern California and Huntington Memorial Hospital. Changing career paths, she completed a second residency in anatomic and clinical pathology, followed by a fellowship in hematopathology at USC and a second fellowship in molecular genomic pathology at the University of Pittsburgh Medical Center. Over the last 18 years, she has collaborated with many molecular research and clinical laboratories at Cedars-Sinai Medical Center, USC, UCLA, UPMC and City of Hope. She believes that discovering and understanding the molecular pathways involved in malignancies will lead to accurate diagnosis, individualized risk assessment and more effective personalized therapies.
As a clinical scientist and physician, her main interests lie in the dissection of the molecular mechanisms leading to the pathogenic events driving cancer transformation in solid tumors and hematopoietic malignancies. She supervises clinical, developmental and regulatory activities of the Clinical Molecular Diagnostic Laboratory, and for last five years has developed and designed multiple complex molecular panels for solid tumors, hematologic cancers and germline predisposition testing. She also serves as a member of multiple disease teams, including melanoma, head and neck, thyroid, neuro-oncology, leukemia, lymphoma, multiple myeloma, neuroendocrine, precision medicine, and phase I therapeutics at City of Hope. As a principal investigator of multiple studies focusing on thyroid cancers, acute myeloid leukemia and Ph-like lymphoblastic leukemia, her work has been presented at many national and international meetings. 


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

In The News